Crinetics Pharmaceuticals Inc (CRNX) Expected to Announce Earnings of -$0.39 Per Share
Wall Street analysts expect that Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) will report earnings of ($0.39) per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Crinetics Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.35) and the lowest estimate coming in at ($0.41). The company is expected to announce its next quarterly earnings report on Wednesday, June 12th.
On average, analysts expect that Crinetics Pharmaceuticals will report full year earnings of ($1.89) per share for the current year, with EPS estimates ranging from ($2.38) to ($1.61). For the next fiscal year, analysts expect that the business will report earnings of ($2.24) per share, with EPS estimates ranging from ($2.55) to ($2.02). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Crinetics Pharmaceuticals.
Crinetics Pharmaceuticals (NASDAQ:CRNX) last issued its quarterly earnings results on Wednesday, March 13th. The company reported ($0.35) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.41) by $0.06. Crinetics Pharmaceuticals had a negative net margin of 1,117.52% and a negative return on equity of 38.38%. The firm had revenue of $0.78 million for the quarter, compared to analyst estimates of $0.32 million.
Shares of Crinetics Pharmaceuticals stock opened at $23.79 on Friday. The firm has a market capitalization of $573.22 million and a PE ratio of -10.67. Crinetics Pharmaceuticals has a 52-week low of $19.23 and a 52-week high of $42.00.
In related news, major shareholder Vivo Capital Fund Viii, L.P. sold 417,000 shares of the stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $22.25, for a total value of $9,278,250.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Ventures Iv L.P. 5Am sold 262,153 shares of the stock in a transaction dated Tuesday, January 22nd. The stock was sold at an average price of $21.88, for a total transaction of $5,735,907.64. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 833,992 shares of company stock valued at $18,769,003.
Institutional investors have recently modified their holdings of the stock. Rhumbline Advisers bought a new position in shares of Crinetics Pharmaceuticals in the 4th quarter worth about $254,000. TIAA CREF Investment Management LLC bought a new position in shares of Crinetics Pharmaceuticals in the 3rd quarter worth about $268,000. Vanguard Group Inc. bought a new position in shares of Crinetics Pharmaceuticals in the 3rd quarter worth about $7,103,000. Bank of New York Mellon Corp bought a new position in shares of Crinetics Pharmaceuticals in the 3rd quarter worth about $453,000. Finally, Emory University bought a new position in shares of Crinetics Pharmaceuticals in the 4th quarter worth about $2,577,000. Institutional investors own 69.68% of the company’s stock.
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly.
Further Reading: What are convertible shares?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.